Abstract
Hepatitis B reactivation can occur with cytotoxic chemotherapy in patients with hepatitis B and cancer. Reactivation can occur in a patient with chronic hepatitis, an inactive carrier, or one with resolved hepatitis. Clinical presentation may range from subclinical elevation of liver enzymes to fatal fulminant hepatic failure. Mammalian target of rapamycin inhibitors, which include everolimus, are a new generation of targeted agents that are currently approved for many cancers (since March 2009) including advanced hormone receptor positive, human epidermal growth factor receptor 2-negative breast cancer, in conjunction with exemestane (as of July 2012). We are therefore still learning the various adverse events that occur with this new class of agents. Here, we present an unfortunate case of fatal hepatitis B reactivation in a woman with metastatic breast cancer treated with everolimus and exemestane. We have detailed the controversies around hepatitis B screening prior to immunosuppressive therapy. Clinicians and patients should be aware of this rare but fatal complication prior to everolimus use, and a detailed history, screening for hepatitis B and prophylactic antiviral treatment should be considered.
Similar content being viewed by others
References
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. doi:10.1056/NEJMoa1109653
Pazdur R (2013) FDA Approval of everolimus. http://www.cancer.gov/cancertopics/druginfo/fda-everolimus. Accessed 15 Aug 2013
AFINITOR Package insert. Novartis Pharma
Sezgin Goksu S, Bilal S, Coskun HS (2013) Hepatitis B reactivation related to everolimus. World J Hepatol 5(1):43–45. doi:10.4254/wjh.v5.i1.43
Mizuno S, Yamagishi Y, Ebinuma H, Nakamoto N, Katahira M, Sasaki A, Sakamoto M, Suzuki H, Kanai T, Hibi T (2013) Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol 6(2):188–192. doi:10.1007/s12328-013-0371-4
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, Rad001 in Advanced Neuroendocrine Tumors TTSG (2011) Everolimus for advanced pancreatic neuroendocrine tumors. New Eng J Med 364(6):514–523. doi:10.1056/NEJMoa1009290
Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. New Eng J Med 363(19):1801–1811. doi:10.1056/NEJMoa1001671
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125–132. doi:10.1016/S0140-6736(12)61134-9
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456. doi:10.1016/S0140-6736(08)61039-9
Oketani M, Ido A, Uto H, Tsubouchi H (2012) Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42(7):627–636. doi:10.1111/j.1872-034X.2012.00998.x
Maynard JE (1990) Hepatitis B: global importance and the need for control. Vaccine 8 (Suppl):S18–S20
Lok ASF, McMahon BJ (2009) AASLD Practice guideline update: chronic hepatitis B: update 2009. http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.10.1007/s10549-013-2681-0. Accessed 15 Aug 2013
Kowdley KVWCC, Welch S, Roberts H, Brosgart CL (2012) Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 56(2):422–433. doi:10.1002/hep.24804
Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70(4):553–561. doi:10.1002/jmv.10430
Shoushtari AH, Shaw RA (2013) Fulminant hepatitis following chemotherapy treatment for breast cancer. BMJ Case Rep. doi:10.1136/bcr-2012-007017
Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100(1):182–188
Hoofnagle JH (2009) Reactivation of hepatitis B. Hepatology 49(5 Suppl):S156–S165. doi:10.1002/hep.22945
Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A, Italian Association for the Study of the Liver (2007) Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39(5):397–408. doi:10.1016/j.dld.2006.12.017
Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 116(20):4769–4776. doi:10.1002/cncr.25253
Knoll A, Boehm S, Hahn J, Holler E, Jilg W (2004) Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 33(9):925–929. doi:10.1038/sj.bmt.1704457
Ling WH, Soe PP, Pang AS, Lee SC (2013) Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 108(10):1931–1935. doi:10.1038/bjc.2013.225
Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, Kondo T, Toyoshima N, Ota S, Kobayashi S, Hige S, Toubai T, Tanaka J, Imamura M, Asaka M (2005) Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 79(5):616–619
Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90(7):1306–1311. doi:10.1038/sj.bjc.6601699
Manzano-Alonso ML, Castellano-Tortajada G (2011) Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 17(12):1531–1537. doi:10.3748/wjg.v17.i12.1531
Teng CF, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ (2011) Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology 54(4):1199–1207. doi:10.1002/hep.24529
Recommendations for routine testing and follow-up for chronic hepatitis B virus (HBV) infection. Centers for disease control and prevention. http://www.cdc.gov/hepatitis/hbv/PDFs/ChronicHepBTestingFlwUp.pdf. Accessed 15 Aug 2013
Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, Zon RT, Wong SL (2010) American society of clinical oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 28(19):3199–3202. doi:10.1200/JCO.2010.30.0673
Everolimus (RAD001) in Metastatic transitional cell carcinoma of the urothelium, NCT00805129. http://clinicaltrials.gov/show/NCT00805129. Accessed 15 Aug 2013
Study of everolimus added to combined hormonal and radiation therapy for high risk prostate cancer, NCT01642732. http://clinicaltrials.gov/show/NCT01642732. Accessed 15 Aug 2013
Everolimus plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced neuroendocrine tumors (GI or Lung Origin) (RADIANT-4), NCT01524783. http://clinicaltrials.gov/show/NCT01524783. Accessed 15 Aug 2013
S1207 Hormone therapy with or without everolimus in treating patients with breast cancer, NCT01674140.. http://clinicaltrials.gov/ct2/show/NCT01674140?term=swog+1207&rank=1. Accessed 15 Aug 2013
Phase III Study of RAD001 Adjuvant Therapy in poor risk patients with diffuse large B-cell lymphoma (DLBCL) of RAD001 versus matching placebo After patients have achieved complete response with first-line rituximab-chemotherapy (PILLAR2), NCT00790036. http://clinicaltrials.gov/show/NCT00790036. Accessed 15 Aug 2013
Daily everolimus in combination with trastuzumab and vinorelbine in HER2/neu positive women with locally advanced or metastatic breast cancer (BOLERO-3), NCT01007942.http://clinicaltrials.gov/show/NCT01007942. Accessed 15 Aug 2013
Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER+Metastatic breast cancer (Bolero-4), NCT01698918. http://clinicaltrials.gov/show/NCT01698918. Accessed 15 Aug 2013
A phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in advance breast cancer. (BOLERO-6), NCT01783444. http://clinicaltrials.gov/show/NCT01783444. Accessed 15 Aug 2013
Porta C, Osanto S, Ravaud A, Climent M-A, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ (2011) Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 47(9):1287–1298. doi:10.1016/j.ejca.2011.02.014
European Association for the Study of the Liver (2009) Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50(2):227–242. doi:10.1016/j.jhep.2008.10.001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Teplinsky, E., Cheung, D., Weisberg, I. et al. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat 141, 167–172 (2013). https://doi.org/10.1007/s10549-013-2681-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-013-2681-0